Add BrightSurf on Google Email

Search results for “Survival”

1,000+ results for "Survival"

Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer

The EORTC trial found that perioperative chemotherapy with FOLFOX4 increases progression-free survival compared to surgery alone, but no significant difference in overall survival was observed. The study concludes that perioperative chemotherapy should remain the reference treatment for patients with resectable liver metastases from co...

Pancreatic cancer patient survival 'significantly higher' with nab-paclitaxel, says TGen-led study

The study found that nab-paclitaxel plus gemcitabine led to significantly improved overall survival and progression-free survival compared to gemcitabine alone. Participants who received nab-paclitaxel also experienced a delay in tumor growth and higher survival rates, with 35% surviving over 1 year.

SourceThe Translational Genomics Research Institute·JournalNew England Journal of Medicine·DateOct 16, 2013

Medicare spending for advanced cancer not linked to survival differences

A study published in the Journal of the National Cancer Institute found that Medicare spending for advanced cancer patients does not correlate with survival rates. Despite significant regional differences in spending, researchers discovered a strong link between higher spending and more frequent hospital visits.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateMar 12, 2013

Study shows bone metastases treatment can improve overall survival

A study published in the Journal of Thoracic Oncology found that denosumab was associated with significantly improved overall median survival in lung cancer patients, including those with non-small-cell lung cancer and small-cell lung cancer. The treatment also showed improved survival in patients with squamous cell carcinoma.

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·DateNov 15, 2012

Study says VeriStrat predicts response but not survival benefit from erlotinib

A study published in the Journal of Thoracic Oncology found that VeriStrat can predict response to erlotinib, but does not provide a survival benefit. The test showed a significant difference in median survival between good and poor responders, with good responders experiencing longer survival on erlotinib.

SourceInternational Association for the Study of Lung Cancer·JournalJournal of Thoracic Oncology·DateOct 15, 2012

Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer

The combination of anastrozole and fulvestrant improved overall survival and progression-free survival in postmenopausal women with hormone receptor-positive metastatic breast cancer. The study showed a six-month extended median survival time compared to anastrozole alone, and improved median time to disease progression.

SourceMichigan Medicine - University of Michigan·JournalNew England Journal of Medicine·DateAug 1, 2012

DNA repair pathway score for predicting chemotherapy response in ovarian cancer patients

A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateApr 13, 2012

Study reports steady increases in long-term survival among children with acute lymphoblastic leukemia, reflecting impact of treatment advances

The study reported a significant increase in five-year and 10-year survival rates for children with acute lymphoblastic leukemia, rising to 90.4% and 83.9%, respectively. Advances in treatment, including new drugs and supportive care, contributed to the improved outcomes.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateMar 12, 2012